{"id":428938,"date":"2019-09-17T13:04:01","date_gmt":"2019-09-17T13:04:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=428938"},"modified":"2019-09-17T13:04:01","modified_gmt":"2019-09-17T13:04:01","slug":"creative-biolabs-releases-biomarker-identification-selection-service-and-in-vitro-assay-service","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-releases-biomarker-identification-selection-service-and-in-vitro-assay-service_428938.html","title":{"rendered":"Creative Biolabs Releases Biomarker Identification & Selection Service and In Vitro Assay Service"},"content":{"rendered":"

New York, USA, September 17, 2019 <\/strong>Based on a brand-new TAC Engineered T Cell Development Services Platform, Creative Biolabs is committed to serving global clients in both academic and industrial fields with professional one-stop solutions to suit each unique need of any T cell antigen coupler (TAC)<\/a> projects.<\/p>\n

 <\/p>\n

As a novel immunotherapy that overcome the limitations of conventional technology, TAC engineered T cell therapy proved a powerful treatment in both liquid and solid tumors, as well as autoimmune diseases, such as non-small cell lung cancer (NSCLC), colorectal, breast, pancreatic and ovarian cancers. Aiming at lowering the cost of drug development and shortening the time of drug discovery during the development of engineered immune cell<\/a>, Creative Biolabs releases Biomarker Identification & Selection Service and In Vitro<\/em> Assay Service with regulatory expertise.<\/p>\n

 <\/p>\n

A standard TAC Biomarker Identification & Selection not only needs to guarantee target antigen perfectly binds and interacts with the domain but also requires a high-level expression and efficient ability to trigger enough immune response. The Biomarker Identification & Selection Service at Creative Biolabs provides clients with an effective tool for targeting immunogenic epitope to identify and select the TAC biomarker<\/a> in different disease models, including but not limited to:<\/p>\n

 <\/p>\n

Liquid tumors<\/strong>: CD19 for Hodgkin Lymphomas, BCMA for Multiple Myeloma<\/p>\n

Solid tumors:<\/strong> HER2 for Glioblastoma, RORI for Non-Small Cell Lung Cancer<\/p>\n

Autoimmune diseases<\/strong>: Env for Immunodeficiency Syndrome, C2, C4 for Lupus Syndromes<\/p>\n

 <\/p>\n

Through years of efforts to support clients at TAC field, a systematic approach of TAC T cell assays<\/a> for TAC development have been developed by scientists at Creative Biolabs, including but not limited to:<\/p>\n

 <\/p>\n

T Cell Activation Assay<\/strong>: The detection of activation markers on the cell surface, the clonal expansion test of T cells, as well as TCR\/CD3 effector cells detection assay.<\/p>\n

Cytokine Release Assay<\/strong>: Single or multiplex cytokine level analysis for TAC-T cells using multiple animal models, comprehensive cell content analysis for assessment of non-tumor cell targeting of TAC-T therapy; detection on the expression levels multiple memory markers<\/p>\n

Cytotoxicity Assay<\/strong>: Proper tests and reagents for the detection of cell viability and cytotoxicity; specific determination of the mechanism of cell death and sensitive data comparation between holes, plates and days; cytotoxicity analysis on target ratio and cell necrotic risk assessments.<\/p>\n

 <\/p>\n

“Our experienced scientists with Ph.D. levels are trusted partners who can provide the best strategy and protocols customized to suit any TAC engineered T cell project. There are other TAC services available, such as TAC Generation & Optimization, TAC Design & Construction, covering each stage of TAC development.” Introduced by the senior scientist at Creative Biolabs.<\/p>\n

 <\/p>\n

More information on T cell antigen development services can be found at https:\/\/www.creative-biolabs.com\/tac-t<\/a>.<\/p>\n

 <\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Creative Biolabs was founded by scientists who are dedicated to the conquering of cancer. We believe to build up a custom-service-centered business model is important for optimizing the drug development process, leveraging accessible resources, and forming a team of various background to conduct drug discovery in future.  Creative Biolabs is dedicated to improving people’s living standards with advanced TAC biotechnologies to offer a seamless, high-quality, single-source approach for advanced TAC engineered T cell development services to shorten the time-to-clinic and lower drug development costs.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs<\/a>
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/tac-t<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, USA, September 17, 2019 Based on a brand-new TAC Engineered T Cell Development Services Platform, Creative Biolabs is committed to serving global clients in both academic and industrial fields with professional one-stop solutions to suit each unique need … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,411,404],"tags":[],"class_list":["post-428938","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/428938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=428938"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/428938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=428938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=428938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=428938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}